Dravet Syndrome Treatment Market Size & Share, by Seizures Type (Absence Seizures, Tonic Seizures, Photosensitive Seizures, Myoclonic Seizures, Atonic Seizures, Partial Seizures); Diagnosis Type (Magnetic Resonance Imaging, Electroencephalography, SCN1 A Testing); Treatment Type (Seizure Medications, Ketogenic Diet, Vagus Nerve Stimulation); Product (SDGs, TGDs, FGDs); End-user - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5280
  • Published Date: Sep 28, 2023
  • Report Format: PDF, PPT

Companies Dominating the Dravet Syndrome Treatment Landscape

top-features-companies
    • AbbVie Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Cadila Healthcare Ltd.
    • Encoded Therapeutics Inc.
    • Epygenix Therapeutics Inc.
    • H Lundbeck AS
    • Jazz Pharmaceuticals Plc
    • Johnson and Johnson
    • Lupin Ltd.
    • PTC Therapeutics Inc.
    • Stoke Therapeutics Inc.
    • Supernus Pharmaceuticals Inc.
    • Sun Pharmaceutical Industries Ltd.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Cadila Healthcare Ltd. an innovative, global pharmaceutical company received approval from the USFDA for a seizure treatment drug, vigabatrin tablets in the strength of 500 mg, which is capable of reducing the frequency of seizures in both adults and kids who haven't been able to manage their seizures with existing treatments by preventing the breakdown of GABA, a naturally occurring tranquilizer, in the brain.
  • Encoded Therapeutics Inc. received over USD 130 million to fund the initial human clinical studies of ETX101, which was given classifications as an orphan drug and a rare pediatric condition by the American Food and Drug Administration (FDA). Furthermore, ETX101 was created to raise NaV1.1-alpha levels to prepare it for the clinic and beyond, and to attract some of the most knowledgeable senior leaders in gene therapy.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5280
  • Published Date: Sep 28, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing child population and the growing research & development are the major factors driving the growth of the market.

The market size of Dravet Syndrome Treatment is anticipated to attain a CAGR of 11% over the forecast period, i.e., 2024 – 2036.

The major players in the market are Cadila Healthcare Ltd., Encoded Therapeutics Inc., Epygenix Therapeutics Inc., H Lundbeck AS, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., PTC Therapeutics Inc., Stoke Therapeutics Inc.

The SGDs segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying